ANN ARBOR, Mich. & CHICAGO–(BUSINESS WIRE)–Mar 10, 2021–
Penrose TherapeuTx, a pharmaceutical firm targeted on creating modern small-molecule therapies for the remedy of superior cancers, right this moment introduced that Navdeep Chandel, Ph.D. has joined the corporate’s scientific advisory board. Dr. Chandel has greater than 20 years of expertise in mitochondrial analysis and has contributed to important breakthroughs in mitochondrial science, together with understanding its position in most cancers cells. He joins Penrose as the corporate is positioned to start quickly advancing its novel Mitochondrial Modifying Agent (MMA) analysis program.
This press launch options multimedia. View the total launch right here: https://www.businesswire.com/news/home/20210310005049/en/
Dr. Navdeep Chandel, Professor of Drugs Biochemistry and Molecular Genetics at Northwestern College Feinberg Faculty of Drugs. (Picture: Enterprise Wire)
Penrose TherapeuTx, by way of unprecedented tissue-driven pharmacologic insights, has pioneered a next-generation class of MMAs which create a selective mitochondrial vulnerability that in the end results in most cancers cell metabolic collapse. The platform has proven promising preclinical outcomes and the corporate has developed a lead candidate, RP-0320, which is about to advance into medical analysis within the coming 12 months.
“Dr. Chandel has lengthy been on the forefront of mitochondrial analysis and the position they play in most cancers cells, which is extraordinarily related to our cutting-edge MMA platform developed to deal with complicated cancers,” mentioned Mark de Souza, Chief Government Officer at Penrose TherapeuTx. “We’ll proceed constructing our scientific management staff and Dr. Chandel’s deep area data will undoubtedly assist our veteran analysis staff extra quickly advance our science and pipeline.”
Dr. Chandel’s work established that mitochondrial metabolism and reactive oxygen species (ROS) are mandatory for tumorigenesis in vivo which led to the present understanding that each cardio glycolysis and mitochondrial metabolism are important for tumor progress. Just lately, Dr. Chandel and his staff printed findings in Nature that confirmed the mitochondrial electron transport chain (ETC) is critical for tumor progress and its inhibition has demonstrated anti-tumor efficacy together with focused therapies.
“The Penrose medical analysis platform of concentrating on mitochondria in most cancers cells is not only novel however unprecedented, with very promising preclinical outcomes to help the development of the pipeline,” mentioned Dr. Navdeep Chandel. “I sit up for advising Penrose as the corporate enters this subsequent stage of analysis.”
Dr. Chandel is the David W. Cugell, M.D. Professor of Drugs Biochemistry and Molecular Genetics at Northwestern College Feinberg Faculty of Drugs the place he additionally based the Chandel Laboratory. Dr. Chandel graduated from the College of Chicago with a B.S. in arithmetic and Ph.D. in Cell Physiology.
About Penrose TherapeuTx
Penrose TherapeuTx is a U.S.-based pharmaceutical firm targeted on creating modern small-molecule therapies for the remedy of superior cancers. Penrose has pioneered the event of a novel Mitochondrial Modifying Agent (MMA) therapeutic platform designed to generate therapies for tough to deal with cancers by way of a singular cooperative mechanism of motion. Our method has potential broad applicability throughout each hematologic and strong tumors. Study extra at https://penrosetherapeutx.com.
View supply model on businesswire.com:https://www.businesswire.com/news/home/20210310005049/en/
CONTACT: MediaChad Hyett
KEYWORD: ILLINOIS MICHIGAN UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: ONCOLOGY HEALTH GENETICS RESEARCH PHARMACEUTICAL SCIENCE
SOURCE: Penrose TherapeuTx
Copyright Enterprise Wire 2021.
PUB: 03/10/2021 07:00 AM/DISC: 03/10/2021 07:01 AM
Copyright Enterprise Wire 2021.